Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Debt to Equity (2020 - 2023)

Mirum Pharmaceuticals (MIRM) has 4 years of Debt to Equity data on record, last reported at $0.01 in Q1 2023.

  • For Q1 2023, Debt to Equity fell 57.86% year-over-year to $0.01; the TTM value through Mar 2023 reached $0.01, down 57.86%, while the annual FY2022 figure was $0.01, 53.78% down from the prior year.
  • Debt to Equity reached $0.01 in Q1 2023 per MIRM's latest filing, up from $0.01 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.02 in Q2 2021 and bottomed at $0.01 in Q1 2021.
  • Average Debt to Equity over 4 years is $0.01, with a median of $0.01 recorded in 2021.
  • Peak YoY movement for Debt to Equity: soared 163.78% in 2022, then tumbled 57.86% in 2023.
  • A 4-year view of Debt to Equity shows it stood at $0.01 in 2020, then surged by 126.07% to $0.02 in 2021, then plummeted by 53.78% to $0.01 in 2022, then increased by 0.63% to $0.01 in 2023.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were $0.01 in Q1 2023, $0.01 in Q4 2022, and $0.01 in Q3 2022.